Peter Riebling

583 total citations
17 papers, 46 citations indexed

About

Peter Riebling is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Peter Riebling has authored 17 papers receiving a total of 46 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 3 papers in Cardiology and Cardiovascular Medicine and 3 papers in Physiology. Recurrent topics in Peter Riebling's work include Muscle Physiology and Disorders (14 papers), Cardiomyopathy and Myosin Studies (3 papers) and RNA modifications and cancer (2 papers). Peter Riebling is often cited by papers focused on Muscle Physiology and Disorders (14 papers), Cardiomyopathy and Myosin Studies (3 papers) and RNA modifications and cancer (2 papers). Peter Riebling collaborates with scholars based in United States, United Kingdom and Sweden. Peter Riebling's co-authors include Stuart W. Peltz, Gary Elfring, Tuyen Ong, Xiaohui Luo, Robert J. Spiegel, Brian J. Lannutti, Panayiota Trifillis, Matthew Mei, Young‐Choon Moon and Joseph M. Colacino and has published in prestigious journals such as Blood, Neurology and Neuromuscular Disorders.

In The Last Decade

Peter Riebling

14 papers receiving 46 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Riebling United States 3 32 13 10 9 6 17 46
Emilie Chopin France 3 58 1.8× 6 0.5× 8 0.8× 1 0.1× 6 1.0× 3 76
Adolfo López de Munaín Arregui Spain 4 42 1.3× 3 0.2× 8 0.8× 3 0.3× 7 1.2× 5 60
Bianca Berdel Germany 4 48 1.5× 20 1.5× 4 0.4× 5 0.6× 3 0.5× 7 105
S. Kallio Finland 4 22 0.7× 5 0.4× 3 0.3× 15 1.7× 2 0.3× 7 61
Prashila Amatya United States 3 21 0.7× 7 0.5× 11 1.1× 1 0.1× 3 0.5× 5 43
Rachelle Shafei United Kingdom 4 9 0.3× 4 0.3× 2 0.2× 11 1.2× 6 1.0× 11 47
Anna Lehman Canada 4 32 1.0× 5 0.4× 11 1.1× 5 0.6× 8 66
Weronika Kowalczyk Poland 3 30 0.9× 8 0.6× 4 0.4× 3 0.3× 1 0.2× 7 61
Neelam Goyal United States 4 35 1.1× 7 0.5× 5 0.5× 1 0.1× 13 2.2× 13 90
Christopher M. Richmond Australia 4 28 0.9× 2 0.2× 10 1.0× 4 0.4× 6 1.0× 9 49

Countries citing papers authored by Peter Riebling

Since Specialization
Citations

This map shows the geographic impact of Peter Riebling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Riebling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Riebling more than expected).

Fields of papers citing papers by Peter Riebling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Riebling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Riebling. The network helps show where Peter Riebling may publish in the future.

Co-authorship network of co-authors of Peter Riebling

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Riebling. A scholar is included among the top collaborators of Peter Riebling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Riebling. Peter Riebling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Darras, Basil T., Peter Riebling, Edward O’Mara, et al.. (2018). Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy (P2.325). Neurology. 90(15_supplement). 1 indexed citations
3.
Werner, Christian, Xiaohui Luo, Gary Elfring, et al.. (2017). Meta-analyses of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy. Neuropediatrics. 48(S 01). S1–S45.
4.
5.
Riebling, Peter, Ronald Kong, Edward O’Mara, et al.. (2017). A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation Duchenne muscular dystrophy. Neuromuscular Disorders. 27. S218–S218. 1 indexed citations
6.
Riebling, Peter, Marcio Ferreira de Souza, Gary Elfring, et al.. (2017). Slope analysis of 6-minute walk distance as an alternative method to determine treatment effect in trials in Duchenne muscular dystrophy. European Journal of Paediatric Neurology. 21. e94–e94.
7.
Werner, Christian, H. Kröger, Xiaohui Luo, et al.. (2017). Lung Function in Ataluren-Treated, Nonambulatory Patients with Nonsense Mutation Duchenne Muscular Dystrophy from a Long-Term Extension Trial. Neuropediatrics. 48(S 01). S1–S45. 2 indexed citations
8.
McDonald, Craig M., Peter Riebling, Gary Elfring, et al.. (2017). Use of a ≥ 5-second threshold in baseline time to stand from supine to predict disease progression in Duchenne muscular dystrophy. European Journal of Paediatric Neurology. 21. e237–e237. 1 indexed citations
9.
Campbell, Craig, Perry B. Shieh, Thomas Sejersen, et al.. (2016). Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy (P3.164). Neurology. 86(16_supplement). 2 indexed citations
10.
McDonald, Craig M., K. Bushby, M. Tulinius, et al.. (2016). Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (P3.162). Neurology. 86(16_supplement). 2 indexed citations
11.
McDonald, Craig M., H. Lee Sweeney, Xiaohui Luo, et al.. (2016). Use of the Six-Minute Walk Distance (6MWD) Across Duchenne Muscular Dystrophy (DMD) Studies (P3.121). Neurology. 86(16_supplement). 3 indexed citations
12.
Muntoni, Francesco, Xiaohui Luo, Gary Elfring, et al.. (2016). Results of North Star ambulatory assessments in the phase 3 ataluren confirmatory trial in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD). Neuromuscular Disorders. 26. S154–S155. 2 indexed citations
13.
14.
15.
Goemans, Nathalie, Craig Campbell, Craig M. McDonald, et al.. (2016). ACT DMD: Effect of Ataluren on Timed Function Tests (TFTs) in Nonsense Mutation Duchenne Muscular Dystrophy (P3.163). Neurology. 86(16_supplement). 1 indexed citations
16.
Schara, Ulrike, K. Bushby, M. Tulinius, et al.. (2016). Ataluren: Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD). Neuropediatrics. 47(S 01). 1 indexed citations
17.
Weetall, Marla, Thomas W. Davis, Gary Elfring, et al.. (2015). Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation. Clinical Pharmacology in Drug Development. 5(4). 296–305. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emilie Chopin Breakdown of academic impact, for papers by Adolfo López de Munaín Arregui Breakdown of academic impact, for papers by Bianca Berdel Breakdown of academic impact, for papers by S. Kallio Breakdown of academic impact, for papers by Prashila Amatya Breakdown of academic impact, for papers by Rachelle Shafei Breakdown of academic impact, for papers by Anna Lehman Breakdown of academic impact, for papers by Weronika Kowalczyk Breakdown of academic impact, for papers by Neelam Goyal Breakdown of academic impact, for papers by Christopher M. Richmond
Rankless by CCL
2026